Ovarian Hyperstimulation Syndrome after GnRH Agonist Triggering and Freeze-All Protocol? Never Not, Hardly Ever: A Systematic Review of Case Reports
暂无分享,去创建一个
E. Papanikolaou | L. Carbone | C. Alviggi | A. Conforti | F. Cariati | S. Picarelli | I. Strina | G. Iorio | M. Y. Rovetto
[1] R. Vallone,et al. Severe Ovarian Hyperstimulation Syndrome in a Woman With Breast Cancer Under Letrozole Triggered With GnRH Agonist: A Case Report and Review of the Literature , 2021, Frontiers in Reproductive Health.
[2] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.
[3] C. Herndon,et al. Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients , 2021, Journal of Assisted Reproduction and Genetics.
[4] A. Andrisani,et al. Which is the optimal timing for starting chemoprotection with gonadotropin-releasing hormone agonists after oocyte cryopreservation? Reflections on a critical case of ovarian hyperstimulation syndrome. , 2020, Journal of gynecology obstetrics and human reproduction.
[5] M. Saini,et al. Severe early-onset ovarian hyperstimulation syndrome with liver dysfunction in an IVF segmentation cycle , 2020, BMJ Case Reports.
[6] D. Cimadomo,et al. Pharmacogenetics of FSH Action in the Female , 2019, Front. Endocrinol..
[7] S. Seneca,et al. Rare genetic variants potentially involved in ovarian hyperstimulation syndrome , 2018, Journal of Assisted Reproduction and Genetics.
[8] A. S. Laganà,et al. Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman’s age and markers of ovarian reserve , 2018, Archives of Gynecology and Obstetrics.
[9] S. Esteves,et al. Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis , 2018, Human reproduction update.
[10] R. Orvieto,et al. Ovarian hyperstimulation syndrome following GnRH agonist trigger—think ectopic , 2017, Journal of Assisted Reproduction and Genetics.
[11] M. Pisarska,et al. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. , 2016, Fertility and sterility.
[12] J. Bogstad,et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. , 2016, Human reproduction.
[13] Shilpa Sharma,et al. Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis , 2015, Journal of human reproductive sciences.
[14] S. Seneca,et al. Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition , 2015, Journal of Assisted Reproduction and Genetics.
[15] A. Arıcı,et al. The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome , 2015, Seminars in Reproductive Medicine.
[16] F. Gode,et al. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. , 2014, Reproductive biomedicine online.
[17] J. Chan,et al. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'. , 2014, Reproductive biomedicine online.
[18] P. Devroey,et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol. , 2014, Fertility and sterility.
[19] S. Sunkara,et al. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. , 2014, Human reproduction update.
[20] P. Humaidan,et al. GnRH agonist triggering: recent developments. , 2013, Reproductive biomedicine online.
[21] E. Kolibianakis,et al. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study , 2012, Reproductive Biology and Endocrinology.
[22] M. Fritz,et al. Severe ovarian hyperstimulation syndrome after letrozole-gonadotropin stimulation: a case report , 2012, Journal of Assisted Reproduction and Genetics.
[23] G. Griesinger,et al. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study. , 2011, Fertility and sterility.
[24] M. van Wely,et al. GnRHa to trigger final oocyte maturation: a time to reconsider. , 2010, Human reproduction.
[25] H. Kliem,et al. Effect of the luteinising hormone surge on regulation of vascular endothelial growth factor and extracellular matrix-degrading proteinases and their inhibitors in bovine follicles. , 2008, Reproduction, fertility, and development.
[26] E. Metzen,et al. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. , 2006, Fertility and sterility.
[27] P. Humaidan,et al. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. , 2006, Reproductive biomedicine online.
[28] H. Tournaye,et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. , 2006, Fertility and sterility.
[29] Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. , 2004, Fertility and sterility.
[30] K. Osteen,et al. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. , 2003, Endocrine reviews.
[31] B. Berisha,et al. Stimulatory and synergistic effects of luteinising hormone and insulin like growth factor 1 on the secretion of vascular endothelial growth factor and progesterone of cultured bovine granulosa cells. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[32] R. Jaffe,et al. Role of vascular endothelial growth factor in ovarian physiology and pathology. , 2000, Fertility and sterility.
[33] M. Breckwoldt,et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. , 1995, The Journal of clinical endocrinology and metabolism.
[34] L. Kahana,et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. , 1991, Fertility and sterility.
[35] W. Shen,et al. Disappearance of exogenously administered human chorionic gonadotropin. , 1989, Fertility and sterility.
[36] B. Little,et al. Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. , 1968, The Journal of clinical endocrinology and metabolism.